2022 World Conference on Lung Cancer (ePosters)-EP08.01-034. Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy

EP08.01-034. Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy

Back to course

Pdf Summary

A study conducted at the University of Virginia Medical Center investigated the association of sarcopenia, a loss of muscle mass and function, with overall survival in patients with advanced non-small cell lung cancer (NSCLC) who were undergoing concurrent immunotherapy and chemotherapy. The study included 92 patients with locally advanced or metastatic NSCLC who were treated between 2015 and 2021. The primary aim of the study was to determine whether sarcopenia, as measured by the psoas muscle index (PMI), was associated with poor survival in these patients. <br /><br />The results of the study showed that sarcopenia was independently associated with poor survival in the patients with advanced NSCLC who were undergoing concurrent immunotherapy and chemotherapy. The body mass index (BMI) was found to be an insufficient marker for identifying sarcopenic patients with a high risk of poor overall survival. The study suggests that the assessment of muscle mass, which is essential for diagnosing sarcopenia, should be routinely included in NSCLC trials. Further research is needed to explore strategies to improve muscle mass and function in patients with advanced NSCLC.<br /><br />The study also analyzed the baseline characteristics of the patients and found that age, gender, Eastern Cooperative Group performance status, smoking status, histology, and other factors did not have a significant impact on overall survival. However, lower BMI and the presence of sarcopenia were associated with a shorter median overall survival.<br /><br />In conclusion, this study provides evidence of the association between sarcopenia and poor survival in patients with advanced NSCLC receiving concurrent immunotherapy and chemotherapy. The findings highlight the importance of assessing muscle mass in these patients and suggest the need for further research to develop strategies to improve muscle mass and function in this population.

Asset Subtitle

Fabian Johannes Bolte

Meta Tag

Speaker Fabian Johannes Bolte

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

sarcopenia

muscle mass

overall survival

NSCLC

immunotherapy

chemotherapy

psoas muscle index

BMI

diagnosing sarcopenia

research